Hepatitis C virus (HCV) infection is the most common bloodborne infection in the United States, with estimates of 4 million HCV-infected individuals in the United States and 170 million worldwide 1 . Most (70-80%) HCV infections persist and about 30% of individuals with persistent infection develop chronic liver disease, including cirrhosis and hepatocellular carcinoma 2 . Epidemiological, viral and host factors have been associated with the differences in HCV clearance or persistence, and studies have demonstrated that a strong host immune response against HCV favours viral clearance 3,4 . Thus, variation in genes involved in the immune response may contribute to the ability to clear the virus. In a recent genome-wide association study, a single nucleotide polymorphism (rs12979860) 3 kilobases upstream of the IL28B gene, which encodes the type III interferon IFN-l3, was shown to associate strongly with more than a twofold difference in response to HCV drug treatment 5 . To determine the potential effect of rs12979860 variation on outcome to HCV infection in a natural history setting, we genotyped this variant in HCV cohorts comprised of individuals who spontaneously cleared the virus (n 5 388) or had persistent infection (n 5 620). We show that the C/C genotype strongly enhances resolution of HCV infection among individuals of both European and African ancestry. To our knowledge, this is the strongest and most significant genetic effect associated with natural clearance of HCV, and these results implicate a primary role for IL28B in resolution of HCV infection.
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Approximately 30% of individuals spontaneously clear acute HCV infection. Host genetic variation is assumed to explain the heterogeneity in HCV clearance across individuals because such differences occur even after exposure to the same HCV inoculum and because there are ethnic differences in clearance frequency 6, 7 . Variation in genes involved in the immune response has already been linked to outcome of acute HCV infection 8, 9 , presumably owing to alteration in the strength and quality of the immune response. However, most variability in spontaneous HCV clearance remains unexplained.
A recent genome-wide association study of .1,600 individuals chronically infected with hepatitis C participating in a clinical treatment trial with pegylated interferon (IFN)-a and ribavirin identified a single nucleotide polymorphism (SNP) on chromosome 19q13, rs12979860, that was strongly associated with sustained virological response (SVR) 5, 10 . This SNP maps 3 kilobases (kb) upstream of the IL28B gene, which encodes the type III interferon IFN-l3. The C/C genotype was associated with a 2.5 or greater rate (depending on ethnicity) of SVR compared with the T/T genotype, and the C allele was over-represented in a random multi-ethnic population as compared with the chronically infected study cohort, raising the possibility that the C allele may favour spontaneous clearance of HCV.
To address directly the role of the rs12979860 SNP in HCV clearance, we genotyped 1,008 individuals from 6 independent HCV cohorts composed of individuals who cleared virus (n 5 388) and individuals with persistent infection (n 5 620). Genotypes were in Hardy-Weinberg equilibrium in both individuals of African and European ancestry (P 5 0.47 and 0.77, respectively). The frequency of the C allele was significantly greater among individuals of European ancestry than those of African ancestry in both the clearance (P 5 3310 210 ) and persistence groups (P 5 1310 221 ) ( Table 1 ). In both ethnic groups, however, there were significant differences in allele frequencies (C versus T) between the clearance and persistence groups, where the C allele showed greater frequencies in the clearance group than in the persistence group (80.3% versus 66.7% respectively in individuals of European ancestry, P 5 7 3 10 28 ; 56.2% versus 37% respectively in individuals of African ancestry, P 5 1 3 10 25 ).
More striking differences were observed in an analysis of genotype frequencies where patients with the C/C genotype were three times more likely to clear HCV relative to patients with the C/T and T/T genotypes combined (odds ratio (OR) 5 0.33, P , 10 212 for combined ethnic groups; Table 2 and Fig. 1 ). Stratification of this analysis by ethnicity indicated that the strength of the protective C/C effect was similar in individuals of African and European ancestry (OR 5 0.32, P 5 1 3 10 24 and OR 5 0.38, P 5 1 3 10 27 , respectively). However, a comparison of the C/C to the T/T group alone suggested stronger protection conferred by C/C in individuals of African ancestry (OR 5 0.21, P 5 3 3 10 25 ) relative to that in individuals of European ancestry (OR 5 0.50, P 5 0.04), although our power to detect a true difference is limited owing to small sample sizes in some groups. LETTERS Overall, the protective effect of C seems to be primarily recessive, as no significant difference was observed between the C/T and T/T genotypes in individuals of African ancestry, European ancestry, or combined ethnic groups for clearance of HCV (data not shown), and C/C was consistently protective relative to C/T and/or T/T ( Table 2 and Fig. 1 ). These results mirror the protective effect of the C/C genotype on SVR after HCV treatment observed previously 5 , where the protection conferred by the C allele also seemed to be recessive in both their Caucasian and African-American patients.
Some individuals used in this study of HCV were co-infected with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV). To eliminate the possibility that co-infection with these viruses might confound the effect of rs12979860 on HCV outcome, analyses were performed using a multivariate model that included hepatitis B surface antigen status as a co-variate or stratifying by HIV status. Neither of these two chronic viral infections altered the effect of this locus on outcome of an acute HCV infection ( Supplementary  Tables 1 and 2 ). We also tested whether there were any differences in the effect of the protective rs12979860 C allele as a function of the route of HCV acquisition (plasma products versus injection drug use), but found no significant differences between the two groups (data not shown). Finally, adjusting by other host genetic factors that associate with clearance of HCV did not alter the protection conferred by the C/C genotype (Supplementary Information I).
Patients with lower baseline HCV viral load respond more favourably to interferon-a treatment 11, 12 . However, little is known regarding the impact of viral load during acute infection on spontaneous HCV clearance because very few HCV-infected individuals are identified and studied at this early phase 13 . We reasoned that the mechanism of protection of the C/C genotype might also extend to greater control of viral load in the chronic phase, but there was no correlation between rs12979860 genotype and viral load (Supplementary Information II and Supplementary Fig. 1 ). However, differences in viral load assays used in the various cohorts may mask a small correlation, even after conversion to international units.
The frequency of HCV clearance varies markedly across ethnic groups 9 , and differences in allele frequencies for the rs12979860 SNP were observed in the present study (Table 1 ) and in another study 5 . Indeed, the observation that the C allele is less frequent among individuals of African descent relative to those of European descent might explain, in part, the observed discrepancy in the frequency of viral clearance in these two ethnic groups, where clearance occurs in 36.4% of HCV infections in individuals of non-African ancestry, but only in 9.3% of infections in individuals of African ancestry 7 . To gain a greater insight into the geographic frequency distribution of the protective C allele, we genotyped 2,371 individuals from 51 populations worldwide ( Table 3 and Fig. 2a ).
The global pattern of allele frequencies shows a striking pattern in which the allele leading to greater natural HCV clearance is nearly fixed throughout east Asia, has an intermediate frequency in Europe, and is the minor allele in Africa (Fig. 2a) . A comparison of the rs12979860 allele frequency diversity across 32 world populations (as measured by F ST ) with that for 1,062 SNPs typed in these same samples shows that the rs12979860 polymorphism has a greater differential frequency (F ST 5 0.23) than most of the other polymorphisms (mean F ST 5 0.12, standard deviation 5 0.1), falling within the upper 12.5 percentile of the distribution of F ST values (Fig. 2b) . Notably, the high frequencies of the C allele found in north and eastern Asian populations are not reflected in correspondingly high frequencies in their American relatives. Thus, if this locus has been under selection pressure, changes in the selective force that may be dependent on geographical location probably occurred after the allele frequencies and degree of regional differentiation of the rs12979860 C allele. a, The numbers identifying populations are given in colonization of the New World. That a common variant has such a strong impact on hepatitis C may indicate that it has actually been under selection, adding to an emerging interpretation of genomewide association studies whereby common variants rarely have large effects unless they were selected to do so 14 .
The rs12979860 SNP is only 3 kb upstream of the IL28B gene, which encodes the type III interferon IFN-l3, and this SNP is in strong linkage disequilibrium (r 2 . 0.85) with a non-synonymous coding variant in the IL28B gene (213A.G, K70R; rs8103142) 5 . Thus, it is possible that this 213A.G change alters the function of IFN-l3 and explains the genetic data described herein, but functional data will be essential to define the precise biological mechanism. Type III interferons include three members-IFN-l1, IFN-l2 and IFN-l3-and the genes encoding these molecules are clustered on human chromosome 19q13 (refs 15, 16) . They are structurally related to the IL-10 superfamily of cytokines, but share functional characteristics with the type I interferons (IFN-a and IFN-b) in that they are induced by viral infections, signal through the JAK-STAT pathway, and exhibit antiviral activity in vitro 15, 16 . IFN-l1 has been shown to exhibit dose-and time-dependent HCV inhibition, induce increases in levels of interferon-stimulated genes, and enhance the antiviral efficacy of IFN-a 17 . It is possible that IFN-l3 works through a similar mechanism. In vitro, IFN-l3 is at least as potent as IFN-l1 in terms of protecting HepG2 cells from lysis after infection with encephalomyocarditis virus 18 . Severe side effects in HCV treatment have been observed with IFN-a therapy 19 , whereas type III IFN (IFN-l) treatment may exhibit less 'interferon-like' adverse effects because receptors for the three family members are only expressed on a limited number of cell types 20 . Whether IFN-l may serve as an alternative treatment modality for HCV infection is under investigation.
We have shown that the rs12979860 polymorphism upstream of IL28B which was previously associated with HCV treatment response also has a marked impact on natural clearance of HCV and may have been under selection in human history. It is now a priority to determine the mechanisms through which IL28B promotes viral defence and the full range of viruses affected by these mechanisms.
METHODS SUMMARY
Subjects in this study were participants in one of six studies: (1) AIDS Link to Intravenous experience (ALIVE 21 ; n 5 281); (2) Multicentre Hemophilia Cohort Study (MHCS 22 ; n 5 305); (3) Hemophilia Growth and Development Study (HGDS 23 ; n 5 106); (4) Correlates of Resolved Versus Low Level Viremic Hepatitis C Infection in Blood Donors study (REVELL; n 5 85); (5) an HCV clinic cohort in Portland, Oregon, USA (n 5 51); and (6) a cohort of injection drug users from the UK (n 5 180) (see Methods for details). Fifty-one worldwide populations (n 5 2,371) from the ALlele FREquency Database (ALFRED) 24 were also genotyped in this study. Details of sampling and ethnographic information for these populations can be found at http://alfred.med.yale.edu/. All populations were in Hardy-Weinberg equilibrium with the exception of one, the Finnish sample (n 5 33, P 5 0.05). Genotyping was performed using the ABI TaqMan allelic discrimination kit and the ABI7900HT Sequence Detection System (Applied Biosystems). SAS 9.1 (SAS Institute) was used for statistical analyses.
